Clinical Practice Updates (CPUs) are intended to inform clinicians, payors and other interested parties of AGA’s concerning areas of clinical practice and/or technologies that are widely available or new to the practice of gastroenterology. CPUs present the current state-of-the-art and by definition will include a combination of strong, evidence-based information, and when not available, best consensus opinion.
Rohit Loomba, Joseph K. Lim, Heather Patton and Hashem B. El-Serag provide an evidence-based review addressing HCC risk in patients with NAFLD and provide eight Best Practice Advice statements to address key issues in clinical management.
Christopher L. Bowlus, MD, AGAF, Joseph K. Lim, MD, AGAF, Keith D. Lindor, MD, AGAF summarize the best practice advice on the surveillance of hepatobiliary cancers, including cholangiocarcinoma, gallbladder adenocarcinoma and hepatocellular carcinoma, in patients with primary sclerosing cholangitis (PSC). PSC, a chronic inflammatory liver disease characterized by strictures within the intrahepatic and extrahepatic biliary tree, has a global impact with a natural progression toward biliary cirrhosis and liver failure. It is strongly associated with inflammatory bowel disease (IBD), which is present in approximately two-thirds of PSC patients, and significantly increases the risk of colon cancer to greater than that of IBD alone.
Jacqueline G. O’Leary, MD, MPH, AGAF, Charles S. Greenberg, MD, Heather M. Patton, MD, AGAF, FAASLD, Stephen H. Caldwell, MD, FAASLD review the most available data to help practitioners appropriately use anticoagulation and pro-coagulants in their treatment of patients with cirrhosis, who have an altered mechanism of coagulation.
Amit G. Singal, MD, Joseph K. Lim, MD. AGAF, Fasiha Kanwal, MD, MSHS, AGAF evaluate the evidence describing the interaction between direct-acting antiviral (DAA) therapy for hepatitis and hepatocellular carcinoma (HCC) with regard to HCC incidence, HCC recurrence, and DAA efficacy, as well as to summarize best practice advice regarding HCC surveillance and timing of DAA therapy.